| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Telemedicine | 19 | 2025 | 196 | 8.800 |
Why?
|
| Emergency Service, Hospital | 53 | 2026 | 402 | 8.100 |
Why?
|
| Electronic Health Records | 20 | 2025 | 719 | 3.680 |
Why?
|
| Primary Health Care | 13 | 2025 | 729 | 3.520 |
Why?
|
| Triage | 6 | 2026 | 24 | 3.270 |
Why?
|
| Humans | 126 | 2026 | 17622 | 3.170 |
Why?
|
| Male | 94 | 2026 | 10014 | 3.120 |
Why?
|
| Delivery of Health Care, Integrated | 14 | 2026 | 540 | 3.010 |
Why?
|
| Office Visits | 7 | 2025 | 75 | 2.990 |
Why?
|
| Time-to-Treatment | 4 | 2026 | 23 | 2.960 |
Why?
|
| Female | 99 | 2026 | 12715 | 2.920 |
Why?
|
| Middle Aged | 71 | 2026 | 7954 | 2.720 |
Why?
|
| Pulmonary Embolism | 14 | 2025 | 46 | 2.700 |
Why?
|
| Patient Acceptance of Health Care | 11 | 2025 | 380 | 2.680 |
Why?
|
| Adult | 68 | 2026 | 7621 | 2.630 |
Why?
|
| Aged | 61 | 2026 | 6223 | 2.550 |
Why?
|
| Retrospective Studies | 45 | 2026 | 2502 | 2.500 |
Why?
|
| Telephone | 9 | 2025 | 159 | 2.230 |
Why?
|
| Ambulatory Care | 6 | 2025 | 228 | 2.150 |
Why?
|
| Health Expenditures | 5 | 2024 | 72 | 2.090 |
Why?
|
| Diabetes Mellitus | 6 | 2020 | 452 | 1.920 |
Why?
|
| Patient Portals | 4 | 2020 | 23 | 1.880 |
Why?
|
| Anticoagulants | 8 | 2024 | 125 | 1.830 |
Why?
|
| Health Services Accessibility | 8 | 2025 | 269 | 1.800 |
Why?
|
| Decision Support Systems, Clinical | 8 | 2024 | 55 | 1.790 |
Why?
|
| California | 35 | 2026 | 2433 | 1.740 |
Why?
|
| Electronic Mail | 5 | 2021 | 51 | 1.560 |
Why?
|
| Cost Sharing | 7 | 2024 | 28 | 1.530 |
Why?
|
| Atrial Fibrillation | 7 | 2025 | 173 | 1.490 |
Why?
|
| Videoconferencing | 4 | 2021 | 7 | 1.490 |
Why?
|
| Young Adult | 23 | 2025 | 2538 | 1.410 |
Why?
|
| Adolescent | 27 | 2025 | 3625 | 1.410 |
Why?
|
| Pandemics | 8 | 2025 | 295 | 1.390 |
Why?
|
| Medication Adherence | 3 | 2020 | 232 | 1.370 |
Why?
|
| Patient Satisfaction | 5 | 2019 | 193 | 1.340 |
Why?
|
| Cross-Sectional Studies | 16 | 2025 | 1295 | 1.300 |
Why?
|
| Deductibles and Coinsurance | 5 | 2017 | 32 | 1.250 |
Why?
|
| Chronic Disease | 4 | 2019 | 398 | 1.210 |
Why?
|
| Subarachnoid Hemorrhage | 3 | 2025 | 5 | 1.210 |
Why?
|
| Internet | 4 | 2020 | 207 | 1.130 |
Why?
|
| Language | 2 | 2025 | 52 | 1.060 |
Why?
|
| Physicians | 4 | 2023 | 120 | 1.040 |
Why?
|
| Insurance, Health | 5 | 2017 | 169 | 1.030 |
Why?
|
| Health Benefit Plans, Employee | 5 | 2017 | 16 | 1.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2014 | 368 | 1.010 |
Why?
|
| Risk Assessment | 11 | 2025 | 1093 | 1.010 |
Why?
|
| Aged, 80 and over | 21 | 2026 | 1976 | 1.010 |
Why?
|
| Choice Behavior | 2 | 2020 | 45 | 1.000 |
Why?
|
| Hospitalization | 10 | 2026 | 831 | 1.000 |
Why?
|
| Heart Failure | 3 | 2023 | 414 | 0.990 |
Why?
|
| Cardiac Rehabilitation | 1 | 2026 | 6 | 0.960 |
Why?
|
| Myocardial Infarction | 2 | 2026 | 226 | 0.960 |
Why?
|
| Physicians, Primary Care | 3 | 2021 | 63 | 0.940 |
Why?
|
| Shock, Septic | 1 | 2025 | 8 | 0.930 |
Why?
|
| Consumer Behavior | 2 | 2020 | 28 | 0.920 |
Why?
|
| Home Care Services | 1 | 2026 | 34 | 0.920 |
Why?
|
| Cohort Studies | 13 | 2025 | 2502 | 0.920 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2025 | 7 | 0.900 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2024 | 41 | 0.880 |
Why?
|
| Pregnancy Rate | 1 | 2024 | 6 | 0.880 |
Why?
|
| Contraception | 1 | 2024 | 23 | 0.870 |
Why?
|
| Abortion, Induced | 1 | 2024 | 18 | 0.860 |
Why?
|
| Craniocerebral Trauma | 5 | 2021 | 12 | 0.850 |
Why?
|
| United States | 18 | 2025 | 3922 | 0.830 |
Why?
|
| Postoperative Complications | 1 | 2025 | 99 | 0.830 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2023 | 215 | 0.820 |
Why?
|
| Musculoskeletal Pain | 1 | 2023 | 26 | 0.790 |
Why?
|
| Severity of Illness Index | 7 | 2026 | 446 | 0.790 |
Why?
|
| Glycated Hemoglobin A | 3 | 2020 | 179 | 0.780 |
Why?
|
| Financing, Personal | 3 | 2017 | 18 | 0.770 |
Why?
|
| Chest Pain | 4 | 2025 | 15 | 0.760 |
Why?
|
| Hypoglycemic Agents | 2 | 2017 | 259 | 0.750 |
Why?
|
| Specialties, Surgical | 1 | 2022 | 1 | 0.740 |
Why?
|
| Allied Health Personnel | 1 | 2022 | 12 | 0.730 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 383 | 0.730 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 208 | 0.720 |
Why?
|
| Length of Stay | 4 | 2026 | 182 | 0.690 |
Why?
|
| Aftercare | 1 | 2021 | 47 | 0.690 |
Why?
|
| Contrast Media | 1 | 2021 | 9 | 0.680 |
Why?
|
| Warfarin | 4 | 2018 | 72 | 0.680 |
Why?
|
| Multitasking Behavior | 1 | 2021 | 2 | 0.670 |
Why?
|
| Attention | 1 | 2021 | 11 | 0.670 |
Why?
|
| Time Factors | 12 | 2026 | 1038 | 0.660 |
Why?
|
| Child | 13 | 2026 | 2485 | 0.660 |
Why?
|
| Communication | 3 | 2018 | 181 | 0.660 |
Why?
|
| Attitude of Health Personnel | 7 | 2021 | 204 | 0.650 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2025 | 308 | 0.650 |
Why?
|
| Stroke | 6 | 2024 | 309 | 0.630 |
Why?
|
| Insurance Coverage | 6 | 2020 | 99 | 0.630 |
Why?
|
| Machine Learning | 1 | 2020 | 60 | 0.630 |
Why?
|
| Caregivers | 2 | 2019 | 136 | 0.620 |
Why?
|
| Infant | 7 | 2026 | 1228 | 0.620 |
Why?
|
| Acute Coronary Syndrome | 3 | 2025 | 19 | 0.620 |
Why?
|
| Income | 5 | 2016 | 86 | 0.600 |
Why?
|
| Child, Preschool | 7 | 2026 | 1455 | 0.590 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 185 | 0.590 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 258 | 0.590 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 187 | 0.580 |
Why?
|
| Atrial Flutter | 4 | 2023 | 16 | 0.580 |
Why?
|
| Ticlopidine | 3 | 2013 | 16 | 0.570 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2013 | 24 | 0.570 |
Why?
|
| Patient Discharge | 4 | 2024 | 154 | 0.530 |
Why?
|
| Health Maintenance Organizations | 5 | 2013 | 403 | 0.530 |
Why?
|
| Surveys and Questionnaires | 11 | 2025 | 1296 | 0.510 |
Why?
|
| Troponin I | 3 | 2025 | 9 | 0.500 |
Why?
|
| Anti-Bacterial Agents | 3 | 2025 | 152 | 0.500 |
Why?
|
| Intracranial Hemorrhages | 3 | 2013 | 17 | 0.500 |
Why?
|
| Quality of Health Care | 2 | 2015 | 260 | 0.500 |
Why?
|
| Computer Security | 1 | 2016 | 6 | 0.490 |
Why?
|
| Access to Information | 1 | 2016 | 12 | 0.490 |
Why?
|
| Efficiency, Organizational | 2 | 2015 | 26 | 0.490 |
Why?
|
| Motivation | 1 | 2017 | 112 | 0.490 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 36 | 0.490 |
Why?
|
| Asthma | 1 | 2019 | 401 | 0.470 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 190 | 0.470 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2008 | 23 | 0.460 |
Why?
|
| Outpatients | 3 | 2025 | 103 | 0.450 |
Why?
|
| Patient Participation | 1 | 2016 | 124 | 0.450 |
Why?
|
| Continental Population Groups | 2 | 2016 | 283 | 0.440 |
Why?
|
| Pharmacists | 2 | 2025 | 50 | 0.440 |
Why?
|
| Catheterization, Central Venous | 4 | 2014 | 10 | 0.420 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 689 | 0.420 |
Why?
|
| Health Care Costs | 2 | 2012 | 211 | 0.420 |
Why?
|
| Ambulatory Care Facilities | 3 | 2020 | 64 | 0.390 |
Why?
|
| Health Planning | 1 | 2012 | 16 | 0.380 |
Why?
|
| Follow-Up Studies | 5 | 2023 | 1157 | 0.380 |
Why?
|
| Community Participation | 1 | 2012 | 29 | 0.380 |
Why?
|
| Medical Savings Accounts | 1 | 2012 | 1 | 0.370 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2012 | 213 | 0.360 |
Why?
|
| Patient Compliance | 2 | 2018 | 269 | 0.360 |
Why?
|
| Age Factors | 6 | 2020 | 874 | 0.340 |
Why?
|
| Predictive Value of Tests | 5 | 2025 | 346 | 0.340 |
Why?
|
| Preventive Health Services | 1 | 2012 | 147 | 0.340 |
Why?
|
| Medical Oncology | 2 | 2021 | 33 | 0.330 |
Why?
|
| Qualitative Research | 4 | 2022 | 290 | 0.330 |
Why?
|
| Troponin | 3 | 2025 | 11 | 0.330 |
Why?
|
| Appendicitis | 2 | 2020 | 13 | 0.310 |
Why?
|
| Physician-Patient Relations | 3 | 2019 | 168 | 0.310 |
Why?
|
| Interviews as Topic | 5 | 2013 | 324 | 0.300 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 527 | 0.300 |
Why?
|
| Sepsis | 3 | 2014 | 64 | 0.290 |
Why?
|
| Drug Costs | 2 | 2013 | 32 | 0.290 |
Why?
|
| Computed Tomography Angiography | 2 | 2025 | 4 | 0.290 |
Why?
|
| Patient Care Team | 3 | 2021 | 107 | 0.280 |
Why?
|
| Treatment Outcome | 4 | 2026 | 1161 | 0.270 |
Why?
|
| Algorithms | 3 | 2025 | 227 | 0.260 |
Why?
|
| Managed Care Programs | 1 | 2009 | 300 | 0.260 |
Why?
|
| Intensive Care Units | 2 | 2026 | 105 | 0.260 |
Why?
|
| Cluster Analysis | 3 | 2024 | 90 | 0.260 |
Why?
|
| Medicare | 4 | 2022 | 197 | 0.250 |
Why?
|
| Disease Management | 2 | 2019 | 110 | 0.250 |
Why?
|
| Acute Disease | 3 | 2022 | 147 | 0.240 |
Why?
|
| Sodium | 1 | 2026 | 14 | 0.240 |
Why?
|
| Hyponatremia | 1 | 2026 | 6 | 0.240 |
Why?
|
| Medical Order Entry Systems | 2 | 2016 | 10 | 0.240 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2026 | 23 | 0.240 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2025 | 8 | 0.240 |
Why?
|
| Neoplasms | 2 | 2021 | 457 | 0.240 |
Why?
|
| Vasoconstrictor Agents | 1 | 2025 | 6 | 0.230 |
Why?
|
| Electronic Prescribing | 1 | 2025 | 7 | 0.230 |
Why?
|
| Prenatal Diagnosis | 1 | 2025 | 20 | 0.230 |
Why?
|
| Patient Acuity | 1 | 2025 | 9 | 0.230 |
Why?
|
| Personal Health Services | 1 | 2005 | 3 | 0.230 |
Why?
|
| Fibrinolytic Agents | 2 | 2016 | 45 | 0.230 |
Why?
|
| Central Nervous System Stimulants | 1 | 2025 | 28 | 0.230 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2025 | 23 | 0.230 |
Why?
|
| Cold Temperature | 1 | 2025 | 2 | 0.230 |
Why?
|
| Seasons | 1 | 2025 | 116 | 0.230 |
Why?
|
| Pregnancy | 3 | 2025 | 1565 | 0.230 |
Why?
|
| Urinary Tract Infections | 1 | 2025 | 18 | 0.230 |
Why?
|
| Referral and Consultation | 2 | 2024 | 161 | 0.230 |
Why?
|
| Pharmaceutical Services | 1 | 2025 | 36 | 0.230 |
Why?
|
| Respiratory Tract Infections | 1 | 2025 | 59 | 0.230 |
Why?
|
| Population Surveillance | 4 | 2015 | 248 | 0.220 |
Why?
|
| Emergencies | 1 | 2025 | 6 | 0.220 |
Why?
|
| Ritonavir | 1 | 2025 | 14 | 0.220 |
Why?
|
| Surgical Procedures, Operative | 1 | 2025 | 16 | 0.220 |
Why?
|
| Long-Acting Reversible Contraception | 1 | 2024 | 1 | 0.220 |
Why?
|
| Contraception Behavior | 1 | 2024 | 16 | 0.220 |
Why?
|
| Gonorrhea | 2 | 2015 | 19 | 0.220 |
Why?
|
| Geriatric Assessment | 1 | 2025 | 42 | 0.220 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2025 | 70 | 0.220 |
Why?
|
| Pediatrics | 2 | 2024 | 149 | 0.220 |
Why?
|
| Health Care Surveys | 5 | 2014 | 210 | 0.220 |
Why?
|
| Health Equity | 1 | 2025 | 27 | 0.210 |
Why?
|
| Meningitis, Bacterial | 1 | 2024 | 1 | 0.210 |
Why?
|
| Intracranial Aneurysm | 1 | 2024 | 2 | 0.210 |
Why?
|
| Patient Selection | 3 | 2020 | 181 | 0.210 |
Why?
|
| Emergency Treatment | 2 | 2014 | 7 | 0.200 |
Why?
|
| Cholesterol, LDL | 2 | 2015 | 117 | 0.200 |
Why?
|
| Risk Factors | 9 | 2025 | 3291 | 0.200 |
Why?
|
| Hydronephrosis | 1 | 2023 | 2 | 0.200 |
Why?
|
| Ureteral Calculi | 1 | 2023 | 2 | 0.200 |
Why?
|
| Prescription Fees | 1 | 2003 | 4 | 0.190 |
Why?
|
| Electrocardiography | 4 | 2025 | 38 | 0.190 |
Why?
|
| Organizations | 1 | 2022 | 8 | 0.190 |
Why?
|
| Leadership | 1 | 2022 | 36 | 0.180 |
Why?
|
| Back Pain | 1 | 2022 | 32 | 0.180 |
Why?
|
| Head Injuries, Closed | 1 | 2021 | 1 | 0.180 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2021 | 5 | 0.180 |
Why?
|
| Appointments and Schedules | 1 | 2021 | 23 | 0.180 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 6 | 0.170 |
Why?
|
| Workload | 1 | 2021 | 26 | 0.170 |
Why?
|
| Incidence | 3 | 2021 | 1278 | 0.170 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2021 | 67 | 0.170 |
Why?
|
| Socioeconomic Factors | 4 | 2017 | 603 | 0.170 |
Why?
|
| Propensity Score | 1 | 2021 | 80 | 0.160 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 46 | 0.160 |
Why?
|
| Electric Countershock | 2 | 2017 | 13 | 0.160 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2017 | 11 | 0.160 |
Why?
|
| Shock, Cardiogenic | 1 | 2020 | 6 | 0.160 |
Why?
|
| Transportation | 1 | 2020 | 14 | 0.160 |
Why?
|
| Heart Arrest | 1 | 2020 | 27 | 0.160 |
Why?
|
| Syncope | 1 | 2020 | 11 | 0.160 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1107 | 0.160 |
Why?
|
| Occupational Stress | 1 | 2019 | 3 | 0.160 |
Why?
|
| Biomarkers | 3 | 2025 | 302 | 0.160 |
Why?
|
| Self-Management | 1 | 2020 | 27 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 46 | 0.150 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 9 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 20 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 56 | 0.150 |
Why?
|
| Text Messaging | 1 | 2019 | 38 | 0.150 |
Why?
|
| Prospective Studies | 6 | 2020 | 1251 | 0.150 |
Why?
|
| After-Hours Care | 1 | 2018 | 2 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2020 | 115 | 0.140 |
Why?
|
| Neisseria gonorrhoeae | 2 | 2015 | 3 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2017 | 14 | 0.130 |
Why?
|
| Prognosis | 4 | 2024 | 609 | 0.130 |
Why?
|
| Health Status | 3 | 2015 | 291 | 0.130 |
Why?
|
| Australia | 1 | 2017 | 26 | 0.130 |
Why?
|
| Comorbidity | 2 | 2017 | 552 | 0.130 |
Why?
|
| Atherosclerosis | 1 | 2018 | 53 | 0.130 |
Why?
|
| Logistic Models | 6 | 2019 | 866 | 0.130 |
Why?
|
| Continuity of Patient Care | 2 | 2015 | 95 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 35 | 0.130 |
Why?
|
| Demography | 1 | 2016 | 92 | 0.120 |
Why?
|
| Guideline Adherence | 2 | 2015 | 155 | 0.120 |
Why?
|
| Costs and Cost Analysis | 2 | 2015 | 65 | 0.120 |
Why?
|
| Patient Preference | 1 | 2016 | 49 | 0.120 |
Why?
|
| Models, Economic | 1 | 2015 | 17 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 168 | 0.120 |
Why?
|
| Abdominal Pain | 3 | 2020 | 14 | 0.120 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 686 | 0.120 |
Why?
|
| Prescription Drugs | 1 | 2015 | 30 | 0.110 |
Why?
|
| Quality of Life | 2 | 2018 | 505 | 0.110 |
Why?
|
| Poverty | 2 | 2014 | 171 | 0.110 |
Why?
|
| Ceftriaxone | 1 | 2015 | 2 | 0.110 |
Why?
|
| Health Information Exchange | 1 | 2014 | 3 | 0.110 |
Why?
|
| Pneumothorax | 1 | 2014 | 1 | 0.110 |
Why?
|
| Thorax | 1 | 2014 | 5 | 0.110 |
Why?
|
| Censuses | 1 | 2014 | 28 | 0.110 |
Why?
|
| Housing | 1 | 2014 | 37 | 0.110 |
Why?
|
| Hypertension | 1 | 2019 | 486 | 0.110 |
Why?
|
| Quality Improvement | 2 | 2015 | 189 | 0.110 |
Why?
|
| Blood Coagulation Disorders | 1 | 2014 | 2 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 559 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 17 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2014 | 62 | 0.100 |
Why?
|
| Patient Care | 1 | 2013 | 30 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 642 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2014 | 108 | 0.100 |
Why?
|
| Medicare Part D | 1 | 2013 | 15 | 0.100 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2013 | 1 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2012 | 20 | 0.090 |
Why?
|
| Hypolipidemic Agents | 1 | 2012 | 37 | 0.090 |
Why?
|
| Myocardial Revascularization | 2 | 2024 | 13 | 0.090 |
Why?
|
| Consumer Health Information | 1 | 2012 | 12 | 0.090 |
Why?
|
| American Recovery and Reinvestment Act | 1 | 2012 | 2 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2025 | 842 | 0.090 |
Why?
|
| Gastroenteritis | 1 | 2012 | 16 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2012 | 268 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2012 | 61 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 37 | 0.090 |
Why?
|
| Certification | 1 | 2011 | 3 | 0.090 |
Why?
|
| Cause of Death | 1 | 2012 | 179 | 0.090 |
Why?
|
| Registries | 1 | 2013 | 475 | 0.090 |
Why?
|
| Sex Factors | 3 | 2021 | 599 | 0.090 |
Why?
|
| Hospitals, Community | 2 | 2025 | 23 | 0.080 |
Why?
|
| Models, Organizational | 1 | 2010 | 54 | 0.080 |
Why?
|
| Professional Role | 2 | 2025 | 14 | 0.080 |
Why?
|
| Medically Uninsured | 1 | 2010 | 41 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2010 | 60 | 0.080 |
Why?
|
| Patient Care Management | 1 | 2009 | 24 | 0.080 |
Why?
|
| Decision Making | 2 | 2008 | 177 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 302 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2025 | 363 | 0.070 |
Why?
|
| ROC Curve | 2 | 2020 | 73 | 0.070 |
Why?
|
| Emergency Medicine | 1 | 2008 | 5 | 0.070 |
Why?
|
| Glasgow Coma Scale | 2 | 2021 | 3 | 0.070 |
Why?
|
| Drug Utilization | 1 | 2008 | 119 | 0.070 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 88 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 545 | 0.060 |
Why?
|
| Prevalence | 2 | 2023 | 830 | 0.060 |
Why?
|
| Educational Status | 3 | 2014 | 177 | 0.060 |
Why?
|
| Demyelinating Diseases | 1 | 2026 | 4 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2026 | 20 | 0.060 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2025 | 7 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2025 | 5 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2025 | 34 | 0.060 |
Why?
|
| Pediatricians | 1 | 2025 | 16 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2025 | 23 | 0.060 |
Why?
|
| Beverages | 1 | 2025 | 18 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2025 | 50 | 0.060 |
Why?
|
| Trust | 1 | 2025 | 33 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 25 | 0.050 |
Why?
|
| Clinical Protocols | 2 | 2015 | 39 | 0.050 |
Why?
|
| Headache | 1 | 2024 | 14 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2023 | 3 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2023 | 33 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 30 | 0.050 |
Why?
|
| Survival Rate | 2 | 2015 | 252 | 0.050 |
Why?
|
| Fever | 1 | 2023 | 52 | 0.050 |
Why?
|
| Heart Rate | 1 | 2023 | 36 | 0.050 |
Why?
|
| Drugs, Generic | 1 | 2003 | 4 | 0.050 |
Why?
|
| Parents | 1 | 2025 | 301 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2023 | 65 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 55 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2015 | 135 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2003 | 143 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 323 | 0.040 |
Why?
|
| House Calls | 1 | 2020 | 10 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.040 |
Why?
|
| Software | 1 | 2019 | 19 | 0.040 |
Why?
|
| Proxy | 1 | 2019 | 3 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 44 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 116 | 0.040 |
Why?
|
| Nausea | 1 | 2019 | 6 | 0.040 |
Why?
|
| Vomiting | 1 | 2019 | 11 | 0.040 |
Why?
|
| Confidentiality | 1 | 2019 | 23 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 24 | 0.040 |
Why?
|
| Adnexal Diseases | 1 | 1999 | 1 | 0.040 |
Why?
|
| Cysts | 1 | 1999 | 1 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1999 | 1 | 0.040 |
Why?
|
| Proteins | 1 | 1999 | 15 | 0.040 |
Why?
|
| Glucose | 1 | 1999 | 30 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 121 | 0.040 |
Why?
|
| Migraine Disorders | 1 | 2019 | 18 | 0.040 |
Why?
|
| Medicaid | 1 | 2020 | 188 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 19 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 114 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 2015 | 5 | 0.030 |
Why?
|
| Cross Infection | 1 | 2015 | 24 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2015 | 25 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 24 | 0.030 |
Why?
|
| Documentation | 1 | 2015 | 38 | 0.030 |
Why?
|
| Cephalosporin Resistance | 1 | 2015 | 1 | 0.030 |
Why?
|
| Doxycycline | 1 | 2015 | 2 | 0.030 |
Why?
|
| Cephalosporins | 1 | 2015 | 6 | 0.030 |
Why?
|
| Azithromycin | 1 | 2015 | 3 | 0.030 |
Why?
|
| Meaningful Use | 1 | 2014 | 4 | 0.030 |
Why?
|
| Sexual Partners | 1 | 2015 | 36 | 0.030 |
Why?
|
| Sentinel Surveillance | 1 | 2014 | 13 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 104 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2014 | 3 | 0.030 |
Why?
|
| Inservice Training | 1 | 2014 | 13 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2014 | 45 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2014 | 58 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 87 | 0.020 |
Why?
|
| Random Allocation | 1 | 2013 | 33 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 36 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2015 | 163 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 2012 | 2 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 3 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2012 | 12 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2013 | 214 | 0.020 |
Why?
|
| Physical Examination | 1 | 2012 | 20 | 0.020 |
Why?
|
| Self Report | 1 | 2014 | 262 | 0.020 |
Why?
|
| Community Health Workers | 1 | 2012 | 13 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 32 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2012 | 73 | 0.020 |
Why?
|
| Cryptosporidium | 1 | 2012 | 1 | 0.020 |
Why?
|
| Serotyping | 1 | 2012 | 2 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2014 | 256 | 0.020 |
Why?
|
| Economic Recession | 1 | 2012 | 4 | 0.020 |
Why?
|
| Salmonella | 1 | 2012 | 2 | 0.020 |
Why?
|
| Antidiarrheals | 1 | 2012 | 2 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 2012 | 5 | 0.020 |
Why?
|
| Foodborne Diseases | 1 | 2012 | 5 | 0.020 |
Why?
|
| Unemployment | 1 | 2012 | 12 | 0.020 |
Why?
|
| Comprehensive Health Care | 1 | 2012 | 8 | 0.020 |
Why?
|
| Financing, Government | 1 | 2012 | 25 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 228 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 2011 | 26 | 0.020 |
Why?
|
| Feces | 1 | 2012 | 89 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 492 | 0.020 |
Why?
|
| Medical Staff | 1 | 2010 | 1 | 0.020 |
Why?
|
| Denmark | 1 | 2010 | 19 | 0.020 |
Why?
|
| Physicians, Family | 1 | 2010 | 36 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 14 | 0.020 |
Why?
|
| New York City | 1 | 2010 | 24 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2009 | 22 | 0.020 |
Why?
|
| Family Practice | 1 | 2009 | 41 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2004 | 631 | 0.010 |
Why?
|
| Health Behavior | 1 | 2004 | 348 | 0.010 |
Why?
|
| Cyst Fluid | 1 | 1999 | 2 | 0.010 |
Why?
|